Harmonization of immune biomarker assays for clinical studies.
about
Cancer classification using the Immunoscore: a worldwide task forceImmunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsTargeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapyTowards the introduction of the 'Immunoscore' in the classification of malignant tumoursThe simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform.Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.Managing Multi-center Flow Cytometry Data for Immune Monitoring.Estimating point and interval frequency of antigen-specific CD4+ T cells based on short in vitro expansion and improved poisson distribution analysisDevelopment and implementation of a proficiency testing program for Luminex bead-based cytokine assays.The immuno-oncology framework: Enabling a new era of cancer therapy.Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring.Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoring.Ancillary study management systems: a review of needs.Overnight resting of PBMC changes functional signatures of antigen specific T- cell responses: impact for immune monitoring within clinical trials.Classification of current anticancer immunotherapiesA harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)The effects of storage temperature on PBMC gene expression.Profiling the immune stromal interface in breast cancer and its potential for clinical impactPhase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problemsHarmonization of Clinical Laboratory Information - Current and Future StrategiesImmunotherapy biomarkers 2016: overcoming the barriers.Immunological Monitoring to Rationally Guide AAV Gene Therapy.Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays.Towards a commercial process for the manufacture of genetically modified T cells for therapy.Adoptive T-cell therapy: a need for standard immune monitoring.Automated Analysis of Flow Cytometry Data to Reduce Inter-Lab Variation in the Detection of Major Histocompatibility Complex Multimer-Binding T Cells.Implementing liquid biopsies into clinical decision making for cancer immunotherapy.Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics.The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study.Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis.Introduction to a Special Issue of the Journal of Immunological Methods: Building global resource programs to support HIV/AIDS clinical trial studies.Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells.Harmonization of the intracellular cytokine staining assay.Ex-vivo whole blood secretion of interferon (IFN)-γ and IFN-γ-inducible protein-10 measured by enzyme-linked immunosorbent assay are as sensitive as IFN-γ enzyme-linked immunospot for the detection of gluten-reactive T cells in human leucocyte antigTrial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance.
P2860
Q21245495-53F57725-2CAC-44CB-B66B-6D7E3135F9FAQ26765115-B2E1B8E7-8027-4724-A11D-D1D3D5CF2D1FQ26991589-2781591F-4F9C-4F06-B4EE-19A29AB93661Q27026489-F184422C-5C86-4564-B8EB-82A35509D820Q30528191-1C38E461-5617-44BE-B0CC-1160039FC5B4Q30538743-675936A2-438E-48D4-9D31-1DF93F8372CEQ30620607-15CED758-18AE-4064-ACE1-A09ED0E698DCQ30927297-D7C1E65F-2C39-4ADE-BCAF-3ED49DDE82C0Q30974350-1E27B4AE-5AC3-44E7-BCEF-26E088CB0D8EQ31082473-8FBCED46-73BD-41A9-8DF3-C6D208A5B875Q34066926-8012EEF2-5A18-48E4-84F0-359A791C89C9Q34284462-423AEF61-83F9-446C-9FD4-16E0977DD26DQ34333155-777FBB21-0D8F-4803-81E2-1132F444AB2FQ34522294-C6B332E2-0012-4036-8A5D-59CAA9140921Q34530756-6D865149-1EBD-45F2-954A-AE1CEFE4C740Q34538018-F4BA9DCB-BC05-41F3-AC19-24895F255F1FQ35022675-2223BD82-F366-490C-9DE6-F128395A5B5BQ35149637-B3D4DD05-31B6-450F-ADB8-3EE9709D431EQ35646739-4A92908B-487F-4505-A8C9-07B6BFA9F5B0Q35958116-C5EC405B-0472-4255-AFFC-04382AC4CF42Q36449295-A8FE220C-C3BD-4D4C-B641-C9F011BD1450Q36523499-33658DD5-9FBA-49D2-865B-7A2875DAD336Q36997922-05F5143F-A685-420B-91E6-D5610B77332EQ37155127-4AF7C0C8-1029-4F58-B347-94A07511A28CQ37713438-C994E316-D7B2-446D-A49C-E3FF8192A94AQ38142098-0A92D117-1847-4335-B1E8-FF5A16F7D312Q38160232-FA267DBF-7168-4DD0-9813-DB0755DFDAC1Q38329158-38FA0C0D-D955-4E05-A861-DFEA7CDA562EQ38525029-0DDBCD77-5ADB-414D-8683-626F0C50AF04Q38629483-61B80EB1-2450-4AB3-AE72-2553693B5E77Q39304648-8F8A88C4-28AC-46F8-9084-54AA75529171Q39784050-5C94CAAF-9341-4EF1-925E-C4F8A1F426A9Q40428596-EC3E5EC1-5E03-4CA4-8222-97494705338FQ41550516-D64DAE5A-A330-4012-88EA-AA524D99150EQ41642827-735E43ED-D58A-4DA2-9638-6F4EAE28DCD4Q41941058-E43A73CF-FF00-4E07-AB17-7DEBDA105CBFQ42184036-B088056D-EE67-4579-98D2-255A6CD38DC3Q42207308-6B981328-25E3-4E84-AB74-A404FB929C06Q42241774-5ADABAED-C2B6-4009-93FB-C252EA397B15Q42440224-89FE3B81-975A-4124-A7A9-486AA7729B7A
P2860
Harmonization of immune biomarker assays for clinical studies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Harmonization of immune biomarker assays for clinical studies.
@en
Harmonization of immune biomarker assays for clinical studies.
@nl
type
label
Harmonization of immune biomarker assays for clinical studies.
@en
Harmonization of immune biomarker assays for clinical studies.
@nl
prefLabel
Harmonization of immune biomarker assays for clinical studies.
@en
Harmonization of immune biomarker assays for clinical studies.
@nl
P2093
P2860
P1476
Harmonization of immune biomarker assays for clinical studies.
@en
P2093
Cedrik M Britten
Marij J P Welters
Michael Kalos
Pedro Romero
Sjoerd H van der Burg
Sylvia Janetzki
P2860
P304
P356
10.1126/SCITRANSLMED.3002785
P407
P577
2011-11-01T00:00:00Z